$7.185
+0.28
(+4.13%)▲
Insights on Liquidia Corp
Revenue is down for the last 2 quarters, 4.78M → 3.67M (in $), with an average decrease of 23.2% per quarter
Netprofit is up for the last 2 quarters, -23.51M → -15.79M (in $), with an average increase of 48.9% per quarter
In the last 1 year, Seagen, Inc. has given 83.0% return, outperforming this stock by 55.7%
4.73%
Downside
Day's Volatility :7.49%
Upside
2.9%
29.62%
Downside
52 Weeks Volatility :49.15%
Upside
27.74%
Period | Liquidia Corp | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 0.73% | 0.3% | 0.0% |
6 Months | -19.67% | 1.7% | 0.0% |
1 Year | 27.31% | -4.0% | -2.4% |
3 Years | 46.81% | 17.2% | -6.5% |
Market Capitalization | 471.9M |
Book Value | $0.74 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.88 |
Wall Street Target Price | 15.83 |
Profit Margin | 0.0% |
Operating Margin TTM | -404.87% |
Return On Assets TTM | -27.36% |
Return On Equity TTM | -80.52% |
Revenue TTM | 18.3M |
Revenue Per Share TTM | 0.28 |
Quarterly Revenue Growth YOY | 16.2% |
Gross Profit TTM | 13.1M |
EBITDA | -51.9M |
Diluted Eps TTM | -0.88 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.03 |
EPS Estimate Next Year | -1.16 |
EPS Estimate Current Quarter | -0.21 |
EPS Estimate Next Quarter | -0.22 |
What analysts predicted
Upside of 120.32%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 7.3M | ↓ 45.08% |
Net Income | -29.2M | ↑ 82.97% |
Net Profit Margin | -401.68% | ↓ 281.12% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.7M | ↓ 62.7% |
Net Income | -53.1M | ↑ 82.26% |
Net Profit Margin | -2.0K% | ↓ 1561.24% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 8.1M | ↑ 198.2% |
Net Income | -46.4M | ↓ 12.7% |
Net Profit Margin | -574.69% | ↑ 1388.23% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 739.6K | ↓ 90.84% |
Net Income | -57.5M | ↑ 23.93% |
Net Profit Margin | -7.8K% | ↓ 7198.3% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 12.9M | ↑ 1637.81% |
Net Income | -29.8M | ↓ 48.2% |
Net Profit Margin | -231.7% | ↑ 7541.29% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 15.9M | ↑ 23.98% |
Net Income | -38.4M | ↑ 28.82% |
Net Profit Margin | -240.76% | ↓ 9.06% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.9M | ↑ 12.2% |
Net Income | -9.9M | ↓ 41.42% |
Net Profit Margin | -253.29% | ↑ 231.82% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.2M | ↓ 19.22% |
Net Income | -9.4M | ↓ 5.75% |
Net Profit Margin | -295.51% | ↓ 42.22% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 5.4M | ↑ 69.35% |
Net Income | -6.0M | ↓ 36.2% |
Net Profit Margin | -111.32% | ↑ 184.19% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.5M | ↓ 16.18% |
Net Income | -13.1M | ↑ 120.11% |
Net Profit Margin | -292.32% | ↓ 181.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 4.8M | ↑ 6.52% |
Net Income | -23.5M | ↑ 79.05% |
Net Profit Margin | -491.37% | ↓ 199.05% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 3.7M | ↓ 23.15% |
Net Income | -15.8M | ↓ 32.86% |
Net Profit Margin | -429.31% | ↑ 62.06% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 14.8M | ↑ 74.91% |
Total Liabilities | 48.5M | ↑ 81.57% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 49.4M | ↑ 232.93% |
Total Liabilities | 30.7M | ↓ 36.68% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 68.8M | ↑ 39.3% |
Total Liabilities | 33.9M | ↑ 10.3% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 99.5M | ↑ 44.58% |
Total Liabilities | 28.4M | ↓ 16.08% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 93.7M | ↓ 5.83% |
Total Liabilities | 28.5M | ↑ 0.06% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 129.2M | ↑ 37.84% |
Total Liabilities | 38.8M | ↑ 36.23% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 139.1M | ↑ 48.71% |
Total Liabilities | 37.0M | ↓ 3.04% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 132.6M | ↓ 4.68% |
Total Liabilities | 37.5M | ↑ 1.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 129.2M | ↓ 2.54% |
Total Liabilities | 38.8M | ↑ 3.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 128.9M | ↓ 0.21% |
Total Liabilities | 47.3M | ↑ 21.93% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 121.6M | ↓ 5.68% |
Total Liabilities | 60.9M | ↑ 28.89% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 111.6M | ↓ 8.19% |
Total Liabilities | 63.6M | ↑ 4.42% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -24.3M | ↑ 74.17% |
Investing Cash Flow | -2.5M | ↓ 11.82% |
Financing Cash Flow | 28.8M | ↑ 371.63% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -31.8M | ↑ 31.04% |
Investing Cash Flow | -870.9K | ↓ 65.77% |
Financing Cash Flow | 68.8M | ↑ 138.83% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -48.3M | ↑ 51.69% |
Investing Cash Flow | -1.9M | ↑ 112.42% |
Financing Cash Flow | 66.4M | ↓ 3.52% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -54.1M | ↑ 12.14% |
Investing Cash Flow | 247.9K | ↓ 113.4% |
Financing Cash Flow | 63.4M | ↓ 4.48% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -34.0M | ↓ 37.14% |
Investing Cash Flow | -107.2K | ↓ 143.25% |
Financing Cash Flow | 26.3M | ↓ 58.5% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.6M | ↓ 16.01% |
Investing Cash Flow | -587.0K | ↑ 447.47% |
Financing Cash Flow | 65.0M | ↑ 146.82% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.4M | ↓ 13.83% |
Investing Cash Flow | -2.0K | ↑ 0.0% |
Financing Cash Flow | 54.5M | ↑ 440.34% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.8M | ↓ 31.5% |
Investing Cash Flow | -94.0K | ↑ 4600.0% |
Financing Cash Flow | 348.0K | ↓ 99.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.6M | ↓ 20.28% |
Investing Cash Flow | -491.0K | ↑ 422.34% |
Financing Cash Flow | 57.0K | ↓ 83.62% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.5M | ↑ 83.73% |
Investing Cash Flow | -243.0K | ↓ 50.51% |
Financing Cash Flow | 10.0M | ↑ 17356.14% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.6M | ↓ 34.21% |
Investing Cash Flow | -243.0K | ↑ 0.0% |
Financing Cash Flow | -409.0K | ↓ 104.11% |
Sell
Neutral
Buy
Liquidia Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Liquidia Corp | 5.18% | -19.67% | 27.31% | 46.81% | 46.81% |
![]() Moderna, Inc. | 8.62% | -38.31% | -54.89% | -50.93% | 320.86% |
![]() Regeneron Pharmaceuticals, Inc. | -1.38% | 9.73% | 9.82% | 65.7% | 115.07% |
![]() Novo Nordisk A/s | -1.43% | 23.95% | 58.41% | 192.13% | 336.59% |
![]() Seagen, Inc. | 0.74% | 10.42% | 83.05% | 20.41% | 247.89% |
![]() Vertex Pharmaceuticals Incorporated | -8.19% | 7.19% | 13.58% | 55.97% | 97.18% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Liquidia Corp | NA | NA | NA | -1.03 | -0.81 | -0.27 | 0.0 | 0.74 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -12.72 | -0.22 | -0.07 | 0.0 | 35.32 |
![]() Regeneron Pharmaceuticals, Inc. | 23.18 | 23.18 | 1.75 | 42.5 | 0.17 | 0.09 | 0.01 | 234.47 |
![]() Novo Nordisk A/s | 41.18 | 41.18 | 4.02 | 2.67 | 0.89 | 0.22 | 0.01 | 20.77 |
![]() Seagen, Inc. | NA | NA | 18.53 | -4.16 | -0.28 | -0.13 | 0.03 | 13.52 |
![]() Vertex Pharmaceuticals Incorporated | 26.38 | 26.38 | 0.5 | 15.04 | 0.23 | 0.14 | 0.0 | 64.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Liquidia Corp | Buy | $471.9M | 46.81% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $30.4B | 320.86% | 24.73 | -38.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $88.5B | 115.07% | 23.18 | 30.47% |
![]() Novo Nordisk A/s | Buy | $459.0B | 336.59% | 41.18 | 35.11% |
![]() Seagen, Inc. | Hold | $40.2B | 247.89% | NA | -32.61% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.5B | 97.18% | 26.38 | 35.94% |
Caligan Partners LP
BlackRock Inc
Vanguard Group Inc
Kynam Capital Management, LP
Eversept Partners, LLC
State Street Corporation
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Organization | Liquidia Corp |
Employees | 63 |
CEO | Dr. Roger A. Jeffs Ph.D. |
Industry | Health Technology |
Asymmetric Smart Alpha S&p 500 Etf
$7.19
+4.13%
Advisorshares Alpha Dna Equity Sentiment Etf
$7.19
+4.13%
Falcon's Beyond Global Inc
$7.19
+4.13%
Jaguar Global Growth Corporation I
$7.19
+4.13%
Missfresh Ltd
$7.19
+4.13%
Shuaa Partners Acquisition Corp I
$7.19
+4.13%
Rose Hill Acquisition Corp
$7.19
+4.13%
Partners Bancorp
$7.19
+4.13%
Mercantile Bank Corp
$7.19
+4.13%